Decoy Therapeutics Inc.
DCOYNasdaq
$5.61
↓ -6.3%Jul 17 close · end-of-day
Price
1Y↓ -95.1%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$3.0M
Enterprise Value
-$4.8M
P/E
0.1
P/S
—
P/B
0.8
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
$12.0M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
309.6%
ROIC
—
Debt / Equity
—
Net Cash
$7.8M
Return 1Y
-94.9%
Company profile
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company is headquartered in Houston, Texas.
- CEO
- David J. Arthur
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 20
- Headquarters
- Texas
- Website
- salariuspharma.com
Earnings
DCOY Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$4.18↓ -98.3%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $5.2M | $1.8M | $0.00 | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$7.8M | -$12.8M | -$31.8M | -$12.9M | -$5.7M | -$12.6M |
| Net income | -$7.4M | -$12.8M | -$31.6M | $12.5M | $5.6M | $12.5M |
| Diluted EPS | -$0.50 | -$7.72 | -$14.88 | -$30.74 | -$69.54 | -$129.10 |
| Operating cash flow | -$10.3M | -$10.2M | -$17.6M | -$12.8M | -$4.5M | -$4.8M |
| Free cash flow | -$10.3M | -$10.2M | — | — | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -148.8% | -696.3% | — | — | — | — |
| Net margin | -140.5% | -693.8% | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$1.5M | -$1.0M | -$1.5M | -$1.7M | -$965,565.00 | -$895,130.00 | -$9.0M | -$2.3M |
| Net income | -$1.4M | -$972,121.00 | $9.7M | -$1.7M | -$957,825.00 | -$873,467.00 | $16.1M | -$2.2M |
| Diluted EPS | -$2.37 | -$11.38 | -$52.52 | -$240.07 | -$0.45 | -$1.81 | $113.23 | -$4.18 |
| Operating cash flow | -$1.1M | -$1.4M | -$742,518.00 | -$1.2M | -$862,297.00 | -$1.6M | -$1.1M | -$2.9M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2025-12-30 | HANISH ARNOLD C | Sale | 15 | $0.64 | $9.60 | filing |
| 2025-12-30 | HANISH ARNOLD C | Sale | 12 | $0.64 | $7.68 | filing |
| 2025-11-20 | Rosenblum Mark J· Exec VP Finance, CFO | Buy | 20,000 | $0.80 | $16,000.00 | filing |
| 2025-11-20 | HANISH ARNOLD C | Buy | 5,000 | $0.75 | $3,740.50 | filing |
Latest 4 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.